Advanced Gastroesophageal Junction Adenocarcinoma Clinical Trials

15 clinical trials for Advanced Gastroesophageal Junction Adenocarcinoma across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial — RECRUITING · PHASE2
• mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma — RECRUITING · PHASE3
• Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer — RECRUITING · PHASE1
• At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer — RECRUITING · PHASE2
• Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer — RECRUITING · PHASE2
• Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer. — RECRUITING
• CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors — RECRUITING · PHASE2
• Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial — ACTIVE_NOT_RECRUITING · PHASE1
• SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer — NOT_YET_RECRUITING · PHASE2
• Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma — COMPLETED · PHASE1
• Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy — OTHER
• Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC — OTHER · PHASE2

Refine this search